Patient baseline characteristics at time of first relapse (N = 33)
| Characteristic . | N (%) . |
|---|---|
| Age | |
| ≤60 y | 21 (64) |
| >60 y | 12 (36) |
| Sex | |
| Female | 14 (43) |
| Male | 19 (57) |
| Race | |
| Caucasian | 27 (82) |
| Not Caucasian | 6 (18) |
| Hemoglobin | |
| ≥12 g/dL | 28 (85) |
| <12 g/dL | 5 (15) |
| β2-microglobulin | |
| Normal | 9 (27) |
| Elevated | 6 (22) |
| Not done | 18 (51) |
| Lactate dehydrogenase | |
| Normal | 25 (76) |
| Elevated | 8 (24) |
| Bone marrow | |
| Not involved | 15 (45) |
| Involved | 6 (22) |
| Not done | 12 (33) |
| Grade | |
| 1-2 | 23 (70) |
| 3A | 2 (9) |
| Not assessed | 7 (21) |
| Ki-67 | |
| <40% | 19 (55) |
| ≥40% | 2 (9) |
| Not assessed on biopsy | 12 (36) |
| B-symptoms | |
| Absent | 31 (94) |
| Present | 2 (6) |
| Ann Arbor stage | |
| I-II | 1 (3) |
| III-IV | 32 (97) |
| Involved nodal areas | |
| ≤4 | 23 (70) |
| >4 | 10 (30) |
| FLIPI score | |
| Low | 11 (33.5) |
| Intermediate | 13 (39.5) |
| High | 9 (27) |
| SUVmax | |
| ≤10 | 13 (39.5) |
| >10 | 13 (39.5) |
| Not assessed | 7 (21) |
| Characteristic . | N (%) . |
|---|---|
| Age | |
| ≤60 y | 21 (64) |
| >60 y | 12 (36) |
| Sex | |
| Female | 14 (43) |
| Male | 19 (57) |
| Race | |
| Caucasian | 27 (82) |
| Not Caucasian | 6 (18) |
| Hemoglobin | |
| ≥12 g/dL | 28 (85) |
| <12 g/dL | 5 (15) |
| β2-microglobulin | |
| Normal | 9 (27) |
| Elevated | 6 (22) |
| Not done | 18 (51) |
| Lactate dehydrogenase | |
| Normal | 25 (76) |
| Elevated | 8 (24) |
| Bone marrow | |
| Not involved | 15 (45) |
| Involved | 6 (22) |
| Not done | 12 (33) |
| Grade | |
| 1-2 | 23 (70) |
| 3A | 2 (9) |
| Not assessed | 7 (21) |
| Ki-67 | |
| <40% | 19 (55) |
| ≥40% | 2 (9) |
| Not assessed on biopsy | 12 (36) |
| B-symptoms | |
| Absent | 31 (94) |
| Present | 2 (6) |
| Ann Arbor stage | |
| I-II | 1 (3) |
| III-IV | 32 (97) |
| Involved nodal areas | |
| ≤4 | 23 (70) |
| >4 | 10 (30) |
| FLIPI score | |
| Low | 11 (33.5) |
| Intermediate | 13 (39.5) |
| High | 9 (27) |
| SUVmax | |
| ≤10 | 13 (39.5) |
| >10 | 13 (39.5) |
| Not assessed | 7 (21) |
The median age was 56 years (range, 32-85 years). FLIPI, Follicular Lymphoma International Prognostic Index; SUVmax, maximum standardized uptake.